UNASSIGNED: Vaccination during pregnancy has been recommended in some countries as a means to protect young @entity1 from severe @entity281 . Nevertheless, many aspects are still unknown and possible blunting of the @entity1 's immune responses by maternal antibodies, is one of the concerns with maternal vaccination. We report the first prospective controlled cohort study in @entity1 and @entity1 on the effects of using Boostrix(  ), a combined @entity116 , @entity7394 and acellular pertussis vaccine, during pregnancy. The primary aim was to measure the influence of this booster dose on the titer and duration of the presence of maternal antibodies in the @entity1 and assess possible interference with @entity1 immune responses. In a controlled cohort study, 57 pregnant @entity1 were vaccinated with Tdap vaccine ( @entity116 Diphtheria acellular @entity5695 , Boostrix, GSK Biologicals), at a mean gestational age of 28.6 weeks. A control group of pregnant @entity1 (N=42) received no vaccine. Antibody geometric mean concentrations (GMCs) against @entity116 ( @entity116 ), @entity7394 ( @entity7394 ), pertussis toxin (PT), @entity121 ( @entity121 ) and pertactin (Prn) were measured with commercial ELISA tests in samples taken preceding maternal vaccination and one month afterwards, at delivery and from the cord blood, and in @entity1 before and 1 month after the primary series of 3 pertussis containing hexavalent vaccines. @entity1 born to vaccinated @entity1 had significantly higher GMC at birth and during the first 2 months of life for all vaccine antigens compared to the offspring of unvaccinated @entity1 , thereby closing the susceptibility gap for pertussis in @entity1 . However, blunting was noticed for @entity1 @entity7394 and pertussis toxin vaccine responses (p<0.001) in the @entity1 from vaccinated @entity1 after the primary vaccination schedule (weeks 8,12 and 16). Since pertussis vaccination has been recommended during pregnancy already, the results of this study support that recommendation and provide additional scientific evidence to document possible interference by maternal antibodies.

XXXX vaccination during pregnancy in Belgium: Results of a prospective controlled cohort study.

@entity1 :: ('9606', 'Species') :: ['women', 'infants', 'Infants', 'infant'] @entity5695 :: ('MESH:D014917', 'Disease') :: ['Pertussis'] @entity7394 :: ('MESH:D004165', 'Disease') :: ['diphtheria', 'DT'] @entity281 :: ('MESH:D007239', 'Disease') :: ['infection'] @entity116 :: ('MESH:D013746', 'Disease') :: ['tetanus', 'Tetanus', 'TT'] @entity121 :: ('MESH:D009135', 'Disease') :: ['FHA', 'filamentous haemagglutinin']
@entity5695 :: (MESH:D014917,Disease) :: ['Pertussis']
